Molecular Markers and the Promise of Precision Medicine for Interstitial Lung Disease

Chad A Newton; Erica L Herzog

doi:10.1016/j.ccm.2021.03.011

Molecular Markers and the Promise of Precision Medicine for Interstitial Lung Disease

Clin Chest Med. 2021 Jun;42(2):357-364. doi: 10.1016/j.ccm.2021.03.011.

Authors

Chad A Newton¹, Erica L Herzog²

Affiliations

¹ Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8558, USA. Electronic address: Chad.Newton@utsouthwestern.edu.
² Section of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Yale School of Medicine, Yale University, 300 Cedar Street TAC441S, New Haven, CT 06520-8057, USA.

Abstract

Management of patients with interstitial lung disease (ILD) requires accurate classification. However, this process relies on subjective interpretation of nonspecific and overlapping clinical features that could hamper clinical care. The development and implementation of objective biomarkers reflective of specific disease states could facilitate precision-based approaches based on patient-level biology to improve the health of ILD patients. Omics-based studies allow for the seemingly unbiased and highly efficient screening of candidate biomarkers and offer unprecedented opportunities for discovery. This review outlines representative major omics-based discoveries in a well-studied condition, idiopathic pulmonary fibrosis, to develop a roadmap to personalized medicine in ILD.

Keywords: Biomarkers; Interstitial lung disease; Omics; Precision medicine.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Biomarkers
Humans
Idiopathic Pulmonary Fibrosis / diagnosis
Lung Diseases, Interstitial / diagnosis*
Precision Medicine*

Substances

Biomarkers

Abstract

Publication types

MeSH terms

Substances

Grants and funding